Thursday, March 7, 2013
San Diego's leading cancer research centers have joined a new partnership to share their resources in hopes of accelerating innovative cancer treatments.
C3's goals include a greater interaction between the cancer centers, including clinical, translational, basic science and educational. They're also planning organized initiatives, such as symposia, conferences and forums, that expand and deepen scientific and public understanding of cancer and advance the field.
“San Diego’s cancer centers are rapidly unlocking the genetic and molecular mechanisms involved in cancer and are in the vanguard of a new era in cancer science," Tony Hunter, PhD, director of the Salk Institute Cancer Center, said in a UCSD news release.
Hunter said the C3 partnership will allow them to build on the San Diego's foundation of groundbreaking cancer research and harness their collective strengths to produce the next generation of therapies.”
“We are in the midst of a transformative decade in cancer research – one in which we have tools like whole-genome sequencing, high-throughput drug screening and nanotechnology to personalize cancer treatments, delivering medicines where they’ll do the most good and the least harm," stated Kristiina Vuori, MD, PhD, Sanford-Burnham’s president, interim CEO and Cancer Center director.